Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Allergic Reactions

Allergic Reactions

Recombinant DNA

Recombinant DNA

Recombinant DNA

Recombinant DNA

Cross-reactivity

Cross-reactivity

Antigens Involved in Adaptive Immunity

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.

Diversity of Antigen Receptors

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Molecular IgE Sensitization Profiling With Micro-Arrayed Allergen Molecules in Adult Patients With Asthma From the LEAD Cohort: A Precision Medicine Approach.

Allergy·2025

Same author

Subcutaneous Allergen Immunotherapy With Hypoallergenic Bet v 1 Compared to Conventional Extract: Poorer Blocking Antibody Capacity Dominated by IgG<sub>1</sub> Instead of IgG<sub>4</sub>.

Allergy·2025

Same author

Association between asthma and IgG levels specific for rhinovirus and respiratory syncytial virus antigens in children and adults.

The journal of allergy and clinical immunology. Global·2024

Same author

Determinants of immunoglobulin G responses to respiratory syncytial virus and rhinovirus in children and adults.

Frontiers in immunology·2024

Same author

An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu<sup>®</sup> in Austrian Patients with Persistent Allergic Rhinitis.

Drugs - real world outcomes·2024

Same author

Nasal IL-13 production identifies patients with late-phase allergic responses.

The Journal of allergy and clinical immunology·2023

Same journal

Corrigendum.

The Journal of allergy and clinical immunology·2026

Same journal

Comparative Efficacy of Biologic Agents for Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Network Meta-analysis.

The Journal of allergy and clinical immunology·2026

Same journal

Tamoxifen-driven neutrophil reprogramming protects from pulmonary Granulibacter bethesdensis infection in chronic granulomatous disease.

The Journal of allergy and clinical immunology·2026

Same journal

Clinical and transcriptomic characterization of mixed granulocytic COPD phenotype.

The Journal of allergy and clinical immunology·2026

Same journal

Dupilumab outcomes in pediatric asthma by early eosinophil status: post hoc analysis of VOYAGE/EXCURSION.

The Journal of allergy and clinical immunology·2026

Same journal

Maternal antibiotic exposure alters the newborn metabolomic profile and increases the risk of respiratory infections in offspring: a 13-year longitudinal birth cohort study.

The Journal of allergy and clinical immunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Recombinant allergens: what does the future hold?

Rudolf Valenta¹, Katarzyna Niespodziana, Margit Focke-Tejkl

¹Christian Doppler Laboratory for Allergy Research, Medical University of Vienna, Vienna, Austria. rudolf.valenta@meduniwien.ac.at

The Journal of Allergy and Clinical Immunology

|April 5, 2011

Summary

This summary is machine-generated.

Recombinant allergen-based vaccines represent a significant advancement in allergy treatment, overcoming limitations of traditional methods. Ongoing clinical studies show promising results, paving the way for safer and more effective allergy immunotherapy.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Removal and Replacement of Endogenous Ligands from Lipid-Bound Proteins and Allergens

Removal and Replacement of Endogenous Ligands from Lipid-Bound Proteins and Allergens

Published on: February 24, 2021

Related Experiment Videos

Last Updated: Jun 3, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Removal and Replacement of Endogenous Ligands from Lipid-Bound Proteins and Allergens

Removal and Replacement of Endogenous Ligands from Lipid-Bound Proteins and Allergens

Published on: February 24, 2021

Area of Science:

Immunology and biotechnology
Allergy research
Vaccine development

Background:

Allergen-specific immunotherapy (AIT) celebrates its centenary, with recombinant allergen-based vaccines marking 10 years since first use.
Natural allergen extracts present challenges in quality, safety, and efficacy.
Recombinant DNA technology offers a solution for producing defined, safe, and immunogenic allergy vaccines.

Purpose of the Study:

To provide an update on clinical studies involving recombinant allergen-based vaccines.
To introduce a novel strategy for allergen-specific immunotherapy using recombinant fusion proteins.

Main Methods:

Review of clinical trial data for recombinant allergen-based vaccines.
Development of fusion proteins combining viral carriers with non-allergenic allergen peptides.

Main Results:

Several recombinant allergen-based vaccines have successfully completed clinical evaluations, reaching Phase III studies.
The novel fusion protein strategy demonstrates potential for side-effect-free immunotherapy.
This approach may also be applicable for prophylactic allergy vaccination.

Conclusions:

Recombinant allergen-based vaccines offer a safer and more effective alternative to traditional allergen extracts.
Novel fusion protein strategies hold promise for advanced allergen-specific immunotherapy and prophylaxis.
Continued research and clinical evaluation are essential for realizing the full potential of these innovative approaches.